Trial Profile
A prospective, randomized, open label, multicenter study in patients presenting with acute coronary syndromes (ACS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary) ; Heparin
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms SYNERGY
- 14 Sep 2006 Status change
- 22 Oct 2005 New trial record.